Efficacy and safety of Qishen Yiqi drop pill for coronary heart disease: An overview of systematic review and meta-analysis

Abstract

Purpose: To investigate current pieces of evidence on Qishen Yiqi drop pill (QSYQ) in coronary heart disease (CHD). Methods: All systematic reviews (SRs) and meta-analyses (Mas) on QSYQ for CHD were collected by searching six databases and evaluated using the Assessment of Multiple Systematic Reviews 2 (AMSTAR 2). The grading of recommendations assessment, development, and evaluation (GRADE) system was applied to assess the quality of outcomes. Results: Five SRs/MAs were analyzed and twenty-four outcome indicators were reported. The AMSTAR 2 revealed that 3 (12.5 %) of the outcome indicators were of moderate quality, 6 (25 %) were of low quality, and 15 (62.5 %) were of deficient quality. Five SRs/MAs (80 %) described adverse reactions, with two reporting no significant adverse reactions and two reporting minor adverse reactions (p > 0.05). Conclusion: Combining QSYQ with conventional therapy improves CHD patients' electrocardiogram and overall health outcomes. Future high-quality clinical trials and standardized study methods are needed to further investigate the safety of QSYQ.